Cognition Therapeutics (CGTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CGTX Cognition Therapeutics

Watchlist

0.428
-0.012-2.75%

Close Nov 22 16:00 ET

0.429
+0.001+0.30%

Post 20:01 ET

17.77MMarket Cap-445P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Cognition Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 13 07:48 ET · Announcements
Cognition Therapeutics | 8-K: Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
SECNov 13 07:43 ET
Cognition Therapeutics Reports Q3 EPS (25c), Consensus (22c)
TipRanksNov 13 07:36 ET
Cognition Therapeutics Sees Cash Runway Into 2Q25
TipRanksNov 13 07:36 ET
Express News | Cognition Therapeutics Q3 Income From Operations USD -14.463 Million
ReutersNov 13 07:30 ET
Express News | Cognition Therapeutics Q3 Net Income USD -9.937 Million
ReutersNov 13 07:30 ET

Comments

Jaguar8

Oct 31 15:16

NEWS

$Cognition Therapeutics (CGTX.US)$
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
Cognition Therapeutics (NASDAQ: CGTX) presented baseline characteristics of participants in their Phase 2 'SHIMMER' study for dementia with Lewy bodies (DLB) at the CTAD conference. The study includes 130 participants with these key characteristics: mean age of 72.8 years, 81.5% male, 91.5% white, with mild-to-moderate cognitive impairment....

Jaguar8

Oct 23 23:14

Mark your calendar. Alzheimer data presentation Oral (Oct 29) Poster (Oct 29-30)

$Cognition Therapeutics (CGTX.US)$

Jaguar8

Oct 23 23:11

NEWS TODAY

$Cognition Therapeutics (CGTX.US)$
Analyses from Cognition's Positive Phase 2 'SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD
Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE'
Poster Presentation details baseline characteristics from the signal-finding ‘SHIMMER' trial in DLB
PURCHASE, N.Y., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognitio...